{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:30:37Z","timestamp":1783956637838,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"AstraZeneca LP"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.rmed.2011.07.020","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T04:39:05Z","timestamp":1319776745000},"page":"257-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Effect of budesonide\/formoterol pMDI on COPD exacerbations: A double-blind, randomized study"],"prefix":"10.1016","volume":"106","author":[{"given":"Amir","family":"Sharafkhaneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Southard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Uryniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubaldo J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2011.07.020_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.rmed.2003.09.001","article-title":"COPD exacerbation: the importance of a standard definition","volume":"98","author":"Pauwels","year":"2004","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2011.07.020_bib2","series-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (updated 2009)","year":"2009"},{"key":"10.1016\/j.rmed.2011.07.020_bib3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2011.07.020_bib4","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.rmed.2006.10.012","article-title":"Exacerbations and lung function decline in COPD: new insights in current and ex-smokers","volume":"101","author":"Makris","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2011.07.020_bib5","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2011.07.020_bib6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Catalu\u00f1a","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2011.07.020_bib7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1164\/ajrccm.154.4.8887592","article-title":"for the SUPPORT investigators. Outcomes following acute exacerbation of severe chronic obstructive lung disease","volume":"154","author":"Connors","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2011.07.020_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/15412555.2010.481697","article-title":"The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review","volume":"7","author":"Toy","year":"2010","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2011.07.020_bib9","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJM200012283432601","article-title":"Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease","volume":"343","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2011.07.020_bib10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.rmed.2011.07.020_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1183\/09031936.03.00013303","article-title":"Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations","volume":"21","author":"Jones","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.07.020_bib12","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2165\/00003495-200868140-00004","article-title":"Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial","volume":"68","author":"Tashkin","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2011.07.020_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","article-title":"Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial","volume":"69","author":"Rennard","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2011.07.020_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1164\/ajrccm.152.3.7663792","article-title":"Standardization of spirometry, 1994 update","volume":"152","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl A","key":"10.1016\/j.rmed.2011.07.020_bib15","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0954-6111(03)80016-1","article-title":"Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale","volume":"97","author":"Leidy","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2011.07.020_bib16","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1164\/ajrccm.154.6.8970362","article-title":"Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease","volume":"154","author":"Eltayara","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2011.07.020_bib17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021322","article-title":"The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2011.07.020_bib18","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation. The St. George\u2019s Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmed.2011.07.020_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George\u2019s respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2011.07.020_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.07.020_bib21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.07.020_bib22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15412550903140881","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50) on COPD exacerbations and impact on patient outcomes","volume":"6","author":"Anzueto","year":"2009","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2011.07.020_bib23","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.rmed.2008.04.019","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50 microg) or salmeterol (50 microg) on COPD exacerbations","volume":"102","author":"Ferguson","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2011.07.020_bib24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2011.07.020_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/SMJ.0b013e3181836b73","article-title":"Clinical definition of COPD exacerbations and classification of their severity","volume":"102","author":"Caramori","year":"2009","journal-title":"South Med J"},{"key":"10.1016\/j.rmed.2011.07.020_bib26","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0140-6736(09)61250-2","article-title":"Budesonide and the risk of pneumonia: a meta-analysis of individual patient data","volume":"374","author":"Sin","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2011.07.020_bib27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","article-title":"Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease","volume":"175","author":"Kardos","year":"2007","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611111002551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611111002551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:16:01Z","timestamp":1760613361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611111002551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0954611111002551"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2011.07.020","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of budesonide\/formoterol pMDI on COPD exacerbations: A double-blind, randomized study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2011.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}